NCT02223065View on ClinicalTrials.gov

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Saxagliptin

DRUG

Dapagliflozin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY